Source: China – South China Morning PostWuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares.
The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount to their closing price of HK$112 on Wednesday, it said in a filing to Hong Kong’s bourse on Thursday. The stock fell 5.2 per cent to…Read More